Glutamine and arginine improve permeability and tight junction protein expression in methotrexate-treated Caco-2 cells

Clinical Nutrition

Volumn 32, Issue 5, 2013, Pages 863-869

  Beutheu, Stéphanie ^a,b   Ghouzali, Ibtissem ^a,b   Galas, Ludovic ^a,b   Déchelotte, Pierre ^a,b,c   Coëffier, Moïse ^a,b,c  

^a UNIVERSITÉ DE ROUEN   (France)

^b UNIVERSITY OF ROUEN   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Arginine; Chemotherapy; Glutamine; Gut barrier; Signaling pathways

Indexed keywords

6 DIAZO 5 OXONORLEUCINE; ARGININE; CITRULLINE; CYSTEINE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GLUTAMIC ACID; GLUTAMINASE; GLUTAMINE; GLYCINE; HISTIDINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUCINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; OCCLUDIN; PROTEIN ZO1; STRESS ACTIVATED PROTEIN KINASE; TAURINE; TIGHT JUNCTION PROTEIN;

AMINO ACID METABOLISM; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CELLULAR DISTRIBUTION; CELLULAR PARAMETERS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FLUORESCEIN ISOTHIOCYANATE DEXTRAN PARACELLULAR FLUX; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCREENING TEST; TIGHT JUNCTION; TRANSEPITHELIAL ELECTRICAL RESISTANCE;

6-DIAZO-5-OXO-1-NORLEUCINE; ARG; ARGININE; C-JUN N-TERMINAL KINASE; CHEMOTHERAPY; CIT; CITRULLINE; CYS; CYSTEINE; DON; ERK; EXTRACELLULAR SIGNAL-REGULATED KINASE; GLN; GLU; GLUTAMATE; GLUTAMINE; GLY; GLYCINE; GUT BARRIER; HIS; HISTIDINE; INHIBITOR OF KAPPA B FACTOR; IΚBΑ; JNK; LEU; LEUCINE; METHOTREXATE; MTX; NF-ΚB; NUCLEAR FACTOR KAPPA B; SIGNALING PATHWAYS; TAU; TAURINE; TEER; TIGHT JUNCTIONS; TJ; TRANSEPITHELIAL RESISTANCE; ZO; ZONULA OCCLUDENS;

ANTIMETABOLITES, ANTINEOPLASTIC; ARGININE; CACO-2 CELLS; DIETARY SUPPLEMENTS; ENTEROCYTES; FOLIC ACID ANTAGONISTS; GASTROINTESTINAL AGENTS; GLUTAMINE; HUMANS; INTESTINAL MUCOSA; METHOTREXATE; MUCOSITIS; NUCLEIC ACID SYNTHESIS INHIBITORS; OCCLUDIN; PERMEABILITY; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TIGHT JUNCTIONS; UP-REGULATION; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84883555000     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2013.01.014     Document Type: Article

References (36)

1. Keefe D.M., Cummins A.G., Dale B.M., Kotasek D., Robb T.A., Sage R.E. Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci (Lond) 1997, 92:385-389.
2. Stringer A.M., Gibson R.J., Logan R.M., Bowen J.M., Yeoh A.S., Burns J., et al. Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) 2007, 232:96-106.
3. Leblond J., Le Pessot F., Hubert-Buron A., Duclos C., Vuichoud J., Faure M., et al. Chemotherapy-induced mucositis is associated with changes in proteolytic pathways. Exp Biol Med (Maywood) 2008, 233:219-228.
4. Beutheu Youmba S., Belmonte L., Galas L., Boukhettala N., Bole-Feysot C., Dechelotte P., et al. Methotrexate modulates tight junctions through NF-kappaB, MEK, and JNK pathways. JPediatr Gastroenterol Nutr 2012, 54:463-470.
5. Hamada K., Shitara Y., Sekine S., Horie T. Zonula occludens-1 alterations and enhanced intestinal permeability in methotrexate-treated rats. Cancer Chemother Pharmacol 2010, 66:1031-1036.
6. Boukhettala N., Ibrahim A., Aziz M., Vuichoud J., Saudan K.Y., Blum S., et al. Adiet containing whey protein, free glutamine, and transforming growth factor-beta ameliorates nutritional outcome and intestinal mucositis during repeated chemotherapeutic challenges in rats. JNutr 2010, 140:799-805.
7. Xue H., Sawyer M.B., Field C.J., Dieleman L.A., Murray D., Baracos V.E. Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor. JNutr 2008, 138:740-746.
8. Boukhettala N., Leblond J., Claeyssens S., Faure M., Le Pessot F., Bole-Feysot C., et al. Methotrexate induces intestinal mucositis and alters gut protein metabolism independently of reduced food intake. Am J Physiol Endocrinol Metab 2009, 296:E182-E190.
9. Bertrand J, Goichon A, Dechelotte P, Coeffier M. Regulation of intestinal protein metabolism by amino acids. Amino Acids 2012; in press.
10. Coeffier M., Marion-Letellier R., Dechelotte P. Potential for amino acids supplementation during inflammatory bowel diseases. Inflamm Bowel Dis 2010, 16:518-524.
11. Cetiner M., Sener G., Sehirli A.O., Eksioglu-Demiralp E., Ercan F., Sirvanci S., et al. Taurine protects against methotrexate-induced toxicity and inhibits leukocyte death. Toxicol Appl Pharmacol 2005, 209:39-50.
12. Li N., Lewis P., Samuelson D., Liboni K., Neu J. Glutamine regulates Caco-2 cell tight junction proteins. Am J Physiol Gastrointest Liver Physiol 2004, 287:G726-G733.
13. Rhoads M.J., Wu G. Glutamine, arginine, and leucine signaling in the intestine. Amino Acids 2009, 37:111-122.
14. Seth A., Basuroy S., Sheth P., Rao R.K. L-glutamine ameliorates acetaldehyde-induced increase in paracellular permeability in Caco-2 cell monolayer. Am J Physiol Gastrointest Liver Physiol 2004, 287:G510-G517.
15. Kouznetsova L., Bijlsma P.B., van Leeuwen P.A., Groot J.A., Houdijk A.P. Glutamine reduces phorbol-12,13-dibutyrate-induced macromolecular hyperpermeability in HT-29Cl.19A intestinal cells. JParenter Enteral Nutr 1999, 23:136-139.
16. Le Bacquer O., Laboisse C., Darmaun D. Glutamine preserves protein synthesis and paracellular permeability in Caco-2 cells submitted to "luminal fasting". Am J Physiol Gastrointest Liver Physiol 2003, 285:G128-G136.
17. Corl B.A., Odle J., Niu X., Moeser A.J., Gatlin L.A., Phillips O.T., et al. Arginine activates intestinal p70(S6k) and protein synthesis in piglet rotavirus enteritis. JNutr 2008, 138:24-29.
18. Viana M.L., Santos R.G., Generoso S.V., Arantes R.M., Correia M.I., Cardoso V.N. Pretreatment with arginine preserves intestinal barrier integrity and reduces bacterial translocation in mice. Nutrition 2009, 26:218-223.
19. Ramalingam A., Wang X., Gabello M., Valenzano M.C., Soler A.P., Ko A., et al. Dietary methionine restriction improves colon tight junction barrier function and alters claudin expression pattern. Am J Physiol Cell Physiol 2011, 299:C1028-C1035.
20. Skrovanek S., Valenzano M.C., Mullin J.M. Restriction of sulfur-containing amino acids alters claudin composition and improves tight junction barrier function. Am J Physiol Regul Integr Comp Physiol 2007, 293:R1046-R1055.
21. Gennari R., Alexander J.W., Eaves-Pyles T. Effect of different combinations of dietary additives on bacterial translocation and survival in gut-derived sepsis. JParenter Enteral Nutr 1995, 19:319-325.
22. Lecleire S., Hassan A., Marion-Letellier R., Antonietti M., Savoye G., Bole-Feysot C., et al. Combined glutamine and arginine decrease proinflammatory cytokine production by biopsies from Crohn's patients in association with changes in nuclear factor-kappaB and p38 mitogen-activated protein kinase pathways. JNutr 2008, 138:2481-2486.
23. Windmueller H.G., Spaeth A.E. Uptake and metabolism of plasma glutamine by the small intestine. JBiol Chem 1974, 249:5070-5079.
24. Boukhettala N., Claeyssens S., Bensifi M., Maurer B., Abed J., Lavoinne A., et al. Effects of essential amino acids or glutamine deprivation on intestinal permeability and protein synthesis in HCT-8 cells: involvement of GCN2 and mTOR pathways. Amino Acids 2012, 42:375-383.
25. Ma T.Y., Nguyen D., Bui V., Nguyen H., Hoa N. Ethanol modulation of intestinal epithelial tight junction barrier. Am J Physiol 1999, 276:G965-G974.
26. De-Souza D.A., Greene L.J. Intestinal permeability and systemic infections in critically ill patients: effect of glutamine. Crit Care Med 2005, 33:1125-1135.
27. Keefe D.M., Brealey J., Goland G.J., Cummins A.G. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000, 47:632-637.
28. Logan R.M., Stringer A.M., Bowen J.M., Yeoh A.S., Gibson R.J., Sonis S.T., et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 2007, 33:448-460.
29. Li Y., Ping X., Yu B., Liu F., Ni X., Li J. Clinical trial: prophylactic intravenous alanyl-glutamine reduces the severity of gastrointestinal toxicity induced by chemotherapy-a randomized crossover study. Aliment Pharmacol Ther 2009, 30:452-458.
30. Daniele B., Perrone F., Gallo C., Pignata S., De Martino S., De Vivo R., et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut 2001, 48:28-33.
31. Vermeulen M.A., de Jong J., Vaessen M.J., van Leeuwen P.A., Houdijk A.P. Glutamate reduces experimental intestinal hyperpermeability and facilitates glutamine support of gut integrity. World J Gastroenterol 2011, 17:1569-1573.
32. Hayashi M., Sakai T., Hasegawa Y., Nishikawahara T., Tomioka H., Iida A., et al. Physiological mechanism for enhancement of paracellular drug transport. JControl Release 1999, 62:141-148.
33. Maeda T., Miyazono Y., Ito K., Hamada K., Sekine S., Horie T. Oxidative stress and enhanced paracellular permeability in the small intestine of methotrexate-treated rats. Cancer Chemother Pharmacol 2010, 65:1117-1123.
34. Kul M., Vurucu S., Demirkaya E., Tunc T., Aydinoz S., Meral C., et al. Enteral glutamine and/or arginine supplementation have favorable effects on oxidative stress parameters in neonatal rat intestine. JPediatr Gastroenterol Nutr 2009, 49:85-89.
35. Lechowski S., Feilhauer K., Staib L., Coeffier M., Bischoff S.C., Lorentz A. Combined arginine and glutamine decrease release of de novo synthesized leukotrienes and expression of proinflammatory cytokines in activated human intestinal mast cells. Eur J Nutr 2012.
36. Coeffier M., Dechelotte P. Combined infusion of glutamine and arginine: does it make sense?. Curr Opin Clin Nutr Metab Care 2010, 13:70-74.